Ver registro no DEDALUS
Exportar registro bibliográfico

Metrics


Metrics:

Anti-Digoxin Fab Variants Generated by Phage Display (2013)

  • Authors:
  • USP affiliated authors: KALIL FILHO, JORGE ELIAS - FM
  • USP Schools: FM
  • DOI: 10.1007/s12033-012-9564-1
  • Subjects: INSUFICIÊNCIA CARDÍACA (PREVENÇÃO E CONTROLE); FIBRILAÇÃO ATRIAL (PREVENÇÃO E CONTROLE); ANGIOTENSINAS; HOSPITALIZAÇÃO (REDUÇÃO)
  • Language: Inglês
  • Imprenta:
  • Source:
  • Acesso online ao documento

    Online accessDOI or search this record in
    Informações sobre o DOI: 10.1007/s12033-012-9564-1 (Fonte: oaDOI API)
    • Este periódico é de assinatura
    • Este artigo NÃO é de acesso aberto
    • Cor do Acesso Aberto: closed
    Versões disponíveis em Acesso Aberto do: 10.1007/s12033-012-9564-1 (Fonte: Unpaywall API)

    Título do periódico: Molecular Biotechnology

    ISSN: 1073-6085,1559-0305



      Não possui versão em Acesso aberto
    Informações sobre o Citescore
  • Título: Molecular Biotechnology

    ISSN: 1073-6085

    Citescore - 2017: 1.75

    SJR - 2017: 0.643

    SNIP - 2017: 0.625


  • Exemplares físicos disponíveis nas Bibliotecas da USP
    BibliotecaCód. de barrasNúm. de chamada
    FM2348508-10BCSEP 192 2013
    How to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      MURATA, Viviane Midori; SCHMIDT, Mariana Costa Braga; KALIL, Jorge; TSURUTA, Lilian Rumi; MORO, Ana Maria. Anti-Digoxin Fab Variants Generated by Phage Display. Molecular Biotechnology, New Jersey, v. 54, n. 2, p. 269-277, 2013. Disponível em: < http://download.springer.com/static/pdf/478/art%253A10.1007%252Fs12033-012-9564-1.pdf?auth66=1415810092_7802c311ede21bf30914f98ef2de5f1f&ext=.pdf > DOI: 10.1007/s12033-012-9564-1.
    • APA

      Murata, V. M., Schmidt, M. C. B., Kalil, J., Tsuruta, L. R., & Moro, A. M. (2013). Anti-Digoxin Fab Variants Generated by Phage Display. Molecular Biotechnology, 54( 2), 269-277. doi:10.1007/s12033-012-9564-1
    • NLM

      Murata VM, Schmidt MCB, Kalil J, Tsuruta LR, Moro AM. Anti-Digoxin Fab Variants Generated by Phage Display [Internet]. Molecular Biotechnology. 2013 ; 54( 2): 269-277.Available from: http://download.springer.com/static/pdf/478/art%253A10.1007%252Fs12033-012-9564-1.pdf?auth66=1415810092_7802c311ede21bf30914f98ef2de5f1f&ext=.pdf
    • Vancouver

      Murata VM, Schmidt MCB, Kalil J, Tsuruta LR, Moro AM. Anti-Digoxin Fab Variants Generated by Phage Display [Internet]. Molecular Biotechnology. 2013 ; 54( 2): 269-277.Available from: http://download.springer.com/static/pdf/478/art%253A10.1007%252Fs12033-012-9564-1.pdf?auth66=1415810092_7802c311ede21bf30914f98ef2de5f1f&ext=.pdf

    Referências citadas na obra
    Adams, K. F, Jr, Fonarow, G. C., Emermam, C. L., LeJemtel, T. H., Constanzo, M. R., Abraham, W. T., et al. (2005). Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminar observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). American Heart Journal, 149, 209–216.
    Gheorghiade, M., van Veldhuisen, D. J., & Colucci, W. S. (2006). Contemporary use of digoxin in the management of cardiovascular disorders. Circulation, 113, 2556–2564.
    Andrés, V. L. G. (2000). Revisión sistemática sobre la efectividad e indicaciones de los anticuerpos antidigoxina en la intoxicación digitálica. Revista Espanola de Cardiologia, 53, 49–58.
    Antman, E. M., & Smith, T. W. (1985). Digitalis toxicity. Annual Review of Medicine, 36, 357–367.
    Butler, V. P, Jr, & Chen, J. P. (1967). Digoxin-specific antibodies. Proceedings of the National Academy of Sciences of the United States of America, 57, 71–78.
    Smith, T. W., Haber, E., Yetman, L., & Butler,. Jr. (1976). Reversal of advanced digoxin intoxication with Fab fragments of digoxin-specific antibodies. The New England Journal of Medicine, 294, 797–800.
    Butler, V. P, Jr, Schmidt, D. H., Smith, T. W., Haber, E., Raynor, B. D., & Demartini, P. (1977). Effects of sheep digoxin-specific antibodies and their Fab fragments on digoxin pharmacokinetics in dogs. The Journal of Clinical Investigation, 59, 345–359.
    Lapostolle, F., Borron, S. W., Verdier, C., Taboulet, P., Guerrier, G., Adnet, F., et al. (2008). Digoxin-specific Fab fragments as single first-line therapy in digitalis poisoning. Critical Care Medicine, 36, 3014–3018.
    Eichhorn, E. J., & Gheorghiade, M. (2002). Digoxin. Progress in Cardiovascular Diseases, 44, 251–266.
    Flanagan, R. J., & Jones, A. L. (2004). Fab antibody fragments: some applications in clinical toxicology. Drug Safety, 27, 1115–1133.
    Kwong, K. Y. & Rader, C. (2009). E. coli expression and purification of Fab antibody fragments, in Current Protocols in Protein Science, vol. 55 Chapter 6: Purification of Recombinant Proteins (Wiley) pp. 6.10.1, 6.10.14.
    Smith, G. P. (1985). Filamentous fusion phage: Novel expression vectors that display cloned antigens on the virion surface. Science, 228, 1315–1317.
    Orlandi, R., Güssow, D. H., Jones, P. T., & Winter, G. (1989). Cloning immunoglobulin variable domains for expression by the polymerase chain reaction. Proceedings of the National Academy of Sciences of the United States of America, 86, 3833–3837.
    McCafferty, J., Griffiths, A. D., Winter, G., & Chiswell, D. J. (1990). Phage antibodies: Filamentous phage displaying antibody variable domains. Nature, 348, 552–554.
    Barbas, C. F, 3rd, Kang, A. S., Lerner, R. A., & Benkovic, S. J. (1991). Assembly of combinatorial antibody libraries on phage surfaces: The gene III site. Proceedings of the National Academy of Sciences of the United States of America, 88, 7978–7982.
    Clackson, T., Hoogenboom, H. R., Griffiths, A. D., & Winter, G. (1991). Making antibody fragments using phage display libraries. Nature, 352, 624–628.
    Paula De, F. J. (1993) Fração sérica de pacientes urêmicos expandidos com atividade digoxina-símile inibidora da Na+K+ATPase: Isolamento, efeitos biológicos e caracterização com anticorpos monoclonais, Ph.D. thesis, University of São Paulo, São Paulo, BR.
    Kabat, E. A., Wu, T. T., Perry, H. M., Gottesman, K. S., & Foeller, C. (1991). Sequences of proteins of immunological interest. Bethesda, MD: US Department of Health and Human Services, Public Health Sciences, National Institute of Health.
    Barbas, C. F., Burton, D. R., Scott, J. K., & Silverman, G. J. (2001). Phage display: A laboratory manual. New York: Cold Spring Harbor Laboratory Press.
    Tsuruta, L. R., Tomioka, Y., Hishinuma, T., Kato, Y., Itoh, K., Suzuki, T., et al. (2003). Characterization of 11-dehydro-thromboxane B2 recombinant antibody obtained by phage display technology. Prostaglandins Leukotrienes and Essential Fatty Acids, 68, 273–284.
    Erlanger, B. F., & Beiser, S. M. (1964). Antibodies specific for ribonucleosides and ribonucleotides and their reaction with DNA. Proceedings of the National Academy of Sciences of the United States of America, 52, 68–74.
    Altschul, S. F., Gish, W., Miller, W., Myers, E. W., & Lipman, D. J. (1990). Basic local alignment search tool. Journal of Molecular Biology, 215, 403–410.
    Larkin, M. A., Blackshields, G., Brown, N. P., Chenna, R., McGettigan, P. A., McWilliam, H., et al. (2007). ClustalW and ClustalX version 2.0. Bioinformatics, 23, 2947–2948.
    Marks, J. D., Hoogenboom, H. R., Bonnert, T. P., McCafferty, J., Griffiths, A. D., & Winter, G. (1991). By-passing immunization. Human antibodies from V-gene libraries displayed on phage. Journal of Molecular Biology, 222, 581–597.
    Arap, M. A. (2005). Phage display technology—applications and innovations. Genetics and Molecular Biology, 28, 1–9.
    Levy, R., Molineux, I. J., Iverson, B. L., & Georgiou, G. (2007). Isolation of trans-acting genes that enhance soluble expression of scFv antibodies in the E. coli cytoplasm by lambda phage display. Journal of Immunological Methods, 321, 164–173.
    Kuba, H., Furukawa, A., Okajima, T., & Furukawa, K. (2008). Efficient bacterial production of functional antibody fragments using a phagemid vector. Protein Expression and Purification, 58, 292–300.
    Schasfoort, R. B. M., & Tudos, A. J. (2008). Handbook of surface plasmon resonance. Cambridge: Royal Society of Chemistry Publishing.
    Rinderknecht, M., Villa, A., Ballmer-Hofer, K., Neri, D., & Detmar, M. (2010). Phage-derived fully human monoclonal antibody fragments to human vascular endothelial growth factor-C block its interaction with VEGF receptor-2 and 3. PLoS ONE, 5, e11941.
    Hunter, M. M., Margolies, M. N., Ju, A., & Haber, E. (1982). High-affinity monoclonal antibodies to the cardiac glycoside, digoxin. Journal of Immunology, 129, 1165–1172.
    Mudgett-Hunter, M., Anderson, W., Haber, E., & Margolies, M. N. (1985). Binding and structural diversity among high-affinity monoclonal anti-digoxin antibodies. Molecular Immunology, 22, 477–488.
    Schildbach, J. F., Panka, D. J., Parks, D. R., Jager, G. C., Novotny, J., Herzenberg, L. A., et al. (1991). Altered hapten recognition by two anti-digoxin hybridoma variants due to variable region point mutations. Journal of Biological Chemistry, 266, 4640–4647.
    Schildbach, J. F., Near, R. I., Bruccoleri, R. E., Haber, E., Jeffrey, P. D., Ng, S. C., et al. (1993). Heavy chain position 50 is a determinant of affinity and specificity for the anti-digoxin antibody 26-10. Journal of Biological Chemistry, 268, 21739–21747.
    Schildbach, J. F., Shaw, S. Y., Bruccoleri, R. E., Haber, E., Herzenberg, L. A., Jager, G. C., et al. (1994). Contribution of a single heavy chain residue to specificity of an anti-digoxin monoclonal antibody. Protein Science, 3, 737–749.
    Short, M. K., Jeffrey, P. D., Kwong, R. F., & Margolies, M. N. (1995). Contribution of antibody heavy chain CDR1 to digoxin binding analyzed by random mutagenesis of phage-displayed Fab 26-10. Journal of Biological Chemistry, 270, 28541–28550.
    Panka, D. J., Mudgett-Hunter, M., Parks, D. R., Peterson, L. L., Herzenberg, L. A., Haber, E., et al. (1988). Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies. Proceedings of the National Academy of Sciences of the United States of America, 85, 3080–3084.
    Caldas, C., Coelho, V., Kalil, J., Moro, A. M., Maranhão, A. Q., & Brígido, M. M. (2003). Humanization of the anti-CD18 antibody 6.7: An unexpected effect of a framework residue in binding to antigen. Molecular Immunology, 39, 941–952.
    Horwitz, A. H., Nadell, R., Preugschat, F., & Better, M. (1994). Chimeric immunoglobulin light chains are secreted at different levels: Influence of framework-1 amino acids. Molecular Immunology, 31, 683–692.
    Bong, Y. S., Cho, S. H., Nham, S. U., & Lee, Y. I. (1998). Cloning and characterization of cDNAs coding for heavy and light chains of agglutinating monoclonal antibody (HAG12islrh) specific for human red blood cells. Biochimica et Biophysica Acta, 10, 156–158.
    Lai, Y. S., John, J. A., Guo, I. C., Chen, S. C., Fang, K., & Chang, C. Y. (2002). In vitro efficiency of intra- and extracellular immunization with mouse anti-YGNNV antibody against yellow grouper nervous necrosis virus. Vaccine, 20, 3221–3229.
    Argiriadi, M. A., Xiang, T., Wu, C., Ghayur, T., & Borhani, D. W. (2009). Unusual water-mediated antigenic recognition of the proinflammatory cytokine interleukin-18. Journal of Biological Chemistry, 36, 24478–24489.
    Gonçalves, O., Dintinger, T., Lebreton, J., Blanchard, D., & Tellier, C. (2000). Mechanism of an antibody-catalysed allylic isomerization. The Biochemical Journal, 3, 691–698.
    Golinelli-Pimpaneau, B., Goncalves, O., Dintinger, T., Blanchard, D., Knossow, M., & Tellier, C. (2000). Structural evidence for a programmed general base in the active site of a catalytic antibody. Proceedings of the National Academy of Sciences of the United States of America, 18, 9892–9895.
    Costagliola, S., Bonomi, M., Morgenthaler, N. G., Van Durme, J., Panneels, V., Refetoff, S., et al. (2004). Delineation of the discontinuous-conformational epitope of a monoclonal antibody displaying full in vitro and in vivo thyrotropin activity. Molecular Endocrinology, 18, 3020–3034.